Puma Biotechnology, Inc. (NASDAQ: PBYI) shares vaulted 14.8% to $35.25, as the company has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation. Share volume was 325,000, compared to an all-day average of one million
